You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
378 A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020173020
Dec 202046012
Jan 2021130030
Feb 2021178019
Mar 2021132018
Apr 2021164023
May 202158037
Jun 20210034
Jul 20210042
Aug 20210033
Sep 20210035
Oct 202196033
Nov 2021145037
Dec 2021112017
Jan 2022126010
Feb 2022114026
Mar 2022160011
Apr 2022138018
May 2022171025
Jun 2022182031
Jul 2022124021
Aug 2022110016
Sep 2022192034
Oct 2022132021
Nov 2022484032
Dec 2022132012
Jan 2023112011
Feb 2023136017
Mar 2023126013
Apr 2023104013
May 2023132026
Jun 2023120014
Jul 2023120018
Aug 2023128022
Sep 2023188014
Oct 2023140011
Nov 2023240011
Dec 2023128012
Jan 20245204
Feb 202495404
Mar 2024204036
Apr 2024296017
May 2024120012
Jun 2024100018
Jul 2024135019
Aug 2024101021
Sep 2024104015
Total70390975